A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.
Ahamadi M, Mehrotra N, Hanan N, Lai Yee K, Gheyas F, Anton J, Bani M, Boroojerdi B, Smit H, Weidemann J, Macha S, Thuillier V, Chen C, Yang M, Williams-Gray CH, Stebbins GT, Pagano G, Hang Y, Marek K, Venuto CS, Javidnia M, Dexter D, Pedata A, Stafford B, Akalu M, Stephenson D, Romero K, Sinha V; Critical Path for Parkinson’s Consortium.
Ahamadi M, et al. Among authors: gheyas f.
Clin Pharmacol Ther. 2021 Aug;110(2):508-518. doi: 10.1002/cpt.2277. Epub 2021 Jun 12.
Clin Pharmacol Ther. 2021.
PMID: 33894056